Search for: "Eli Lilly & Co."
Results 141 - 160
of 1,010
Sort by Relevance
|
Sort by Date
23 Jan 2018, 7:29 pm
Cir. 2015) (citing Eli Lilly & Co. v. [read post]
16 Jan 2018, 2:26 pm
The decision, in Eli Lilly and Co. v. [read post]
27 Dec 2017, 9:44 am
Last Thursday Eli Lilly & Co., the maker of the testosterone product Axiron, announced to Judge Matthew Kennelly in Illinois that an agreement had been reached to settle claims by people injured by Axiron testosterone. [read post]
19 Dec 2017, 2:40 pm
Cir. 2017).(...)We recently applied Akamai V’s “two-prong test” inEli Lilly, a Hatch-Waxman suit brought by Eli Lillyagainst several defendants seeking to launch a genericversion of Eli Lilly’s chemotherapy drug. 845 F.3d at1362. [read post]
19 Dec 2017, 6:09 am
Eli Lilly & Co. expanded it to the context of multi-district (MDL) litigation. [read post]
7 Dec 2017, 9:34 pm
Seeking approval to market generic versions of Eli Lilly's Axiron® testosterone applicator, Defendants Perrigo Company and Perrigo Israel Pharmaceuticals Ltd., Actavis Laboratories UT, Inc., FKA Watson Laboratories Inc., Lupin Pharmaceuticals, Inc. and Lupin Ltd., and Amneal Pharmaceuticals LLC filed... [read post]
1 Dec 2017, 11:35 am
Big pharma players such as Eli Lilly, Novo Nordisk and Allergan are committed to voluntary price restraints, while companies such as Novartis and Roche are in favor of value-based pricing. [read post]
7 Nov 2017, 11:36 am
The most recent medical journal article we have seen concerning this drug safety issue singles out the SGLT2 inhibitors which contain the active empagliflozin, which are listed below: Jardiance (empagliflozin) — Boehringer Ingelheim Pharmaceuticals — FDA Approval: 2014 Glyxambi (empagliflozin and linagliptin) — Boehringer Ingelheim Pharmaceuticals — FDA Approval: 2015 Synjardy (empagliflozin and metformin hydrochloride) — Boehringer Ingelheim Pharmaceuticals and… [read post]
6 Oct 2017, 2:34 pm
Eli Lilly, the court reaffirmed that written description is determined based on the state of the art as of a patent’s priority date and that evidence which illuminates the state of the art only subsequent to the priority date is not relevant to written description. [read post]
6 Oct 2017, 2:34 pm
Eli Lilly, the court reaffirmed that written description is determined based on the state of the art as of a patent’s priority date and that evidence which illuminates the state of the art only subsequent to the priority date is not relevant to written description. [read post]
1 Oct 2017, 9:43 pm
Eli Lilly & Co. (1996), and culminating in Ariad v. [read post]
25 Sep 2017, 7:22 pm
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
25 Sep 2017, 7:22 pm
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
23 Sep 2017, 12:39 pm
Cir. 2015); Eli Lilly, 845 F.3d at 1370. [read post]
16 Sep 2017, 9:46 am
Eli Lilly & Co., 119 F.3d 1559, 1575 (Fed. [read post]
12 Sep 2017, 4:00 am
The doctrine of collateral estoppel has two requirements: (1) “the identical issue necessarily must have been decided in the prior action and be decisive of the present action,” and (2) “the party to be precluded from relitigating the issue must have had a full and fair opportunity to contest the prior determination” (Kaufman v Eli Lilly & Co., 65 NY2d 449, 455 [1985]; see Ackman v Haberer, 111 AD3d 1378, 1379 [2013]). [read post]
25 Jul 2017, 5:34 am
UNCT/14/2 Eli Lilly & Co. v Government of Canada, (16 March 2017) ICSID At 10:00 on 17 Aug 2017 I shall give a talk to the IP Summer School at Cambridge entitled Bilateral Investment Treaties & Exporters' Rights Post-Brexit. [read post]
13 Jul 2017, 11:10 am
The Middlesex Guildhall, Site of the Supreme Court Photo Christine SmithCreative Commons Attribution Share-Alike 4.0 International LicenceSource Wikipedia Jane Lambert Supreme Court (Lords Neuberger, Mance, Clarke, Sumption and Hodge) Eli Lilly v Actavis UK Ltd and others [2017] UKSC 48 (12 July 2017) What the Appeal was about The pharmaceutical company Eli Lilly and Co (" [read post]
12 Jul 2017, 10:14 am
It will suffice to recall that the case stemmed from a complaint filed by Actavis against Eli Lilly in England seeking a declaration of non-infringement affecting not only England but also France, Italy and Spain. [read post]
12 Jul 2017, 10:14 am
It will suffice to recall that the case stemmed from a complaint filed by Actavis against Eli Lilly in England seeking a declaration of non-infringement affecting not only England but also France, Italy and Spain. [read post]
